DRUG NAME: Formoterol
Therapeutic Class: Bronchodilator
Subclass: Long-acting β2-agonist (LABA)
Speciality: Pulmonology
Schedule (India): Schedule H
Route(s): Inhalation (DPI, MDI, Nebulisation)
Formulations Available in India:
Fixed-Dose Combinations (FDCs) commonly available:
- Formoterol + Budesonide (DPI/MDI)
- Formoterol + Beclomethasone (MDI)
- Formoterol + Fluticasone (DPI)
- Formoterol + Mometasone (DPI)
Primary Indications (Approved / Standard in India)
⮞ 1. Bronchial Asthma — Maintenance Therapy (Moderate to Severe Persistent Asthma)
⚠️ CRITICAL: NEVER use formoterol as monotherapy in asthma. MUST always be combined with an inhaled corticosteroid (ICS).
Clinical Notes:
- Use only as part of ICS+LABA combination therapy
- Corresponds to GINA Step 3/4 therapy in Indian asthma management protocols
- Rapid onset (within 1–3 minutes) makes it suitable for maintenance and reliever therapy (MART) when combined with ICS
- If using MART strategy: additional doses of ICS-formoterol may be taken as needed (max total 72 mcg formoterol/day including maintenance doses — specialist supervision required)
⮞ 2. Chronic Obstructive Pulmonary Disease (COPD) — Maintenance Therapy
Clinical Notes:
- May be used as monotherapy in COPD (unlike asthma)
- Combination with ICS or LAMA preferred in moderate-severe COPD with frequent exacerbations
- Assess inhaler technique and adherence at each visit
Secondary Indications — Adults Only (Off-label, if any)
⮞ Exercise-Induced Bronchoconstriction (Prevention) — OFF-LABEL
Note: Regular daily use for this indication may lead to tolerance; SABA (salbutamol) remains first-line for acute pre-exercise prophylaxis.
⮞ Acute Bronchospasm in COPD (Nebulised Formoterol) — OFF-LABEL
Primary Indications (Approved / Standard in India)
⮞ Moderate to Severe Persistent Asthma (ICS+LABA FDC Only)
⚠️ LABA monotherapy is CONTRAINDICATED in paediatric asthma.
Clinical Notes:
- Use only in combination with inhaled corticosteroid
- DPI use requires adequate inspiratory flow; assess technique
- For children <6 years, MDI with spacer may be considered under specialist guidance
- Monitor growth (height) annually in children on long-term ICS+LABA therapy
Safety Monitoring:
- Heart rate and rhythm assessment
- Watch for paradoxical bronchospasm
- Assess inhaler technique at each visit
- Monitor for tremor, nervousness, sleep disturbances
Secondary Indications — Paediatric Doses (Off-label, if any)
⮞ Nebulised Formoterol for Acute Bronchospasm — OFF-LABEL
Statement: Not recommended in children below 5 years of age except under paediatric pulmonologist supervision with documented failure of standard therapy.
Rationale: Formoterol undergoes hepatic metabolism; renal excretion is minimal.
- Known hypersensitivity to formoterol or any formulation component
- LABA monotherapy in asthma (without concurrent ICS) — associated with increased mortality risk
- Severe or acutely deteriorating asthma (not a rescue medication when used alone)
- Cardiomyopathy with documented arrhythmogenic susceptibility
- Untreated life-threatening arrhythmias
- Cardiovascular disease (ischaemic heart disease, arrhythmias, hypertension) — may cause tachycardia, palpitations
- Diabetes mellitus — may elevate blood glucose; monitor glycaemic control
- Hyperthyroidism — augmented sympathomimetic response
- Seizure disorders — may lower seizure threshold
- Hypokalaemia — risk of worsening, especially with concurrent diuretics or corticosteroids
- QT prolongation or concurrent use of QT-prolonging drugs
- Acute exacerbation of asthma/COPD — not a substitute for rescue SABA; ensure adequate controller therapy
- Tremor (dose-related)
- Palpitations
- Tachycardia
- Headache
- Nervousness/anxiety
- Muscle cramps
- Dry mouth
- Throat irritation or cough (with inhalation)
Plain Formoterol:
Fixed-Dose Combinations (ICS + Formoterol):
- ICS+LABA combinations included in NLEM
- Plain formoterol monotherapy NOT on NLEM (appropriately, as monotherapy discouraged in asthma)
- Government supply: ICS+LABA available under national programmes
- Never LABA Alone in Asthma: Formoterol monotherapy in asthma is associated with increased mortality — always prescribe with ICS; most formulations in India are appropriately available as FDCs
- Rapid Onset LABA: Unlike salmeterol, formoterol has rapid onset (1–3 minutes), making it suitable for MART (Maintenance and Reliever Therapy) protocols with budesonide-formoterol combinations
- COPD vs Asthma: LABA monotherapy is acceptable in COPD but NOT in asthma; always confirm diagnosis before prescribing
- Inhaler Technique Critical: Assess and re-educate on proper DPI/MDI technique at every visit — poor technique is a common cause of apparent treatment failure
- Step-Up Therapy: Formoterol-ICS combinations represent Step 3/4 therapy per GINA-adapted Indian guidelines; consider stepping down if well-controlled for ≥3 months
- Hypokalaemia Awareness: In patients on concurrent diuretics or systemic steroids, monitor serum potassium — additive hypokalaemia risk with LABAs
formoterol; LABA; bronchodilator; asthma; COPD; ICS-LABA; inhaler; maintenance therapy; pulmonology; NLEM-combination; paediatric-use
RxIndia v0.1 — 19 Feb 2026
- CDSCO approved product information
- Indian Pharmacopoeia / National Formulary of India
- NLEM India
- API Textbook of Medicine
- ICMR Asthma Guidelines
- IAP Guidelines for Childhood Asthma
- AIIMS Drug Formulary
- Indian hospital protocols (PGIMER, AIIMS Delhi)
- GINA Guidelines (supportive reference for stepped care approach)
- Goodman & Gilman’s The Pharmacological Basis of Therapeutics